medigraphic.com

2023, Número 6

<< Anterior Siguiente >>

Rev Fac Med UNAM 2023; 66 (6)


Estatinas, una alternativa en el tratamiento de la COVID-19

González-Escandón J, Ordaz-Mayoral D, Pablo-Mancilla V, Vargas-Morales A, Miranda-Zamora R, Díaz-Zagoya JC

Idioma: Español
Referencias bibliográficas: 31
Paginas: 7-16
Archivo PDF: 414.88 Kb.


RESUMEN

Las estatinas son ampliamente utilizadas para el control de los niveles de colesterol en pacientes con hipercolesterolemia, lo cual permite prevenir enfermedades cardiovasculares. Además de controlar la síntesis endógena de colesterol, las estatinas tienen efectos pleiotrópicos diversos, como son las propiedades antiinflamatoria, antioxidante y de inmunomodulación. La enfermedad causada por el virus SARS-CoV-2 (COVID-19) provoca una tormenta de citocinas que contribuye a la generación del síndrome respiratorio agudo, que puede llevar a cuadros graves de esta enfermedad e incluso a la muerte del paciente. Diversos estudios realizados en enfermos con COVID-19 que recibieron estatinas, antes o durante el curso de la enfermedad, registraron cuadros menos graves, estancias hospitalarias más cortas y menor mortalidad. El beneficio de las estatinas en la COVID-19 debe ser explorado más ampliamente, ya que potencialmente pueden contribuir al control de esta pandemia que ha postrado a la humanidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chang L, Yan Y, Wang L. Coronavirus disease 2019: Coronavirusesand blood safety. Transfus Med . 2020;34(2):75-80. doi: 10.1016/j.tmrv.2020.02.003.

  2. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S,Baghbanzadeh M, Aghamohammadi N, Zhang W, HaqueU. The SARS, MERS and novel coronavirus (COVID-19)epidemics, the newest and biggest global health threats: whatlessons have we learned? Int J Epidemiol. 2020;48(3):717-26.doi: 10.1093/ije/dyaa033.

  3. De León-Rodríguez SG, Hernández-Rico B, Olmo-VázquezGD, Cruz-Dávalos I, Bonifaz LC. SARS-CoV-2: previouscoronaviruses, immune response, and development of vaccines.Bol Med Hosp Infant Mex. 2020;77(5):252-61. doi:10.24875/BMHIM.20000191.

  4. Diaz-Arocutipa C, Melgar-Talavera B, Alvarado-Yarasca Á,Saravia-Bartra MM, Cazorla P, Belzusarri I, et al. Statinsreduce mortality in patients with COVID-19: an updatedmeta-analysis of 147 824 patients. Int J Infect Dis [Internet].2021;110:374-81. Disponible en: https://www.sciencedirect.com/science/article/pii/S1201971221006366

  5. Aparici A, Amat-Santos IJLópez-Otero D, Marcos-MangasM, González -Juanatey JR, San Román JA. Impacto de lasestatinas en los pacientes con COVID-19. Rev Esp Cardiol.2020;74(7):637-40. doi: 10.1016/j.recesp.2021.01.009.

  6. Wang H, Yuan Z, Pavel MA, Jablonski SM, Jablonski J,Hobson R, Valente S, Reddy CB, Hansen SB. The role ofhigh cholesterol in age-related COVID-19 lethality. bioRxiv.2021; 2020.05.09.0862249. doi: 10.1101/2020.05.09.086249preprint.

  7. Kunal S, Gupta K, Gupta S. Statins in COVID-19: a new rayof hope. Heart & Lung. 2020;49(6):887-9. doi: 10.1016/j.hrtlng.2020.07.012.

  8. Lima Martínez MM et al. Estatinas en COVID-19: ¿existealgún fundamento? Clin Investig Arterioscler. 2020;32(6):278-81.

  9. Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins,and COVID-19: Basic concepts and clinical applications.Biochim Biophys Acta Mol Cell Biol Lipids [Internet].2021;1866(2):158849. Disponible en: https://www.sciencedirect.com/science/article/pii/S1388198120302419

  10. Randa HD, Laurence LB. Goodman & Gilman. Manualde Farmacología y Terapéutica, 2a Ed. México: McGrawHill; 2015. pp. 584-5.

  11. Orlowski S, Mourad J-J, Gallo A, Bruckert E. Coronaviruses,cholesterol and statins: Involvement and applicationfor Covid-19. Biochimie [Internet]. 2021;189:51-64. Disponibleen: https://www.sciencedirect.com/science/article/pii/S0300908421001516

  12. Myers KD, Wilemon K, McGowan MP, Howard W, StaszakD, Rader DJ. COVID-19 associated risks of myocardial infarctionin persons with familial hypercholesterolemia withor without ASCVD. Am J Prev Cardiol. 2021;7:100197. doi:10.1016/j.ajpc.2021.100197.

  13. Rezaei A, Neshat S, Heshmat-Ghahdarijani K. Alterationsof lipid profile in COVID-19: A narrative review. CurrProbl Cardiol [Internet]. 2022;47(3):100907. Disponibleen: https://www.sciencedirect.com/science/article/pii/S0146280621001225

  14. Augustine R, S A, Nayeem A, Salam SA, Augustine P,Dan P, et al. Increased complications of COVID-19 inpeople with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. ChemBiol Interact [Internet]. 2022;351(109738):109738. Disponibleen: https://www.sciencedirect.com/science/article/pii/S0009279721003768

  15. Minz MM, Bansal M, Kasliwal RR. Statins and SARSCoV-2 disease: Current concepts and possible benefits.Diabetes Metab Syndr [Internet]. 2020;14(6):2063-7. Disponible en: https://www.sciencedirect.com/science/article/pii/S1871402120304094

  16. Know CS, Hasan SS. Meta-analysis of effect of statins inpatients with COVID-19. Am J Cardiol. 2020;134;153-5.doi: 10.1016.jam.jcard.2020.08.004.

  17. Khani E, Khiali S, Beheshtirouy S, Entezari-Maleki T. Potentialpharmacologic treatments for COVID-19 smell andtaste loss: A comprehensive review. Eur J Pharmacol [Internet].2021;912(174582):174582. Disponible en: https://www.sciencedirect.com/science/article/pii/S001429992100738X

  18. Kashour T, Halwani R, Arabi YM, Sohail MR, O’HoroJC, Badley AD, Tleyjeh IM. Statins as an adjunctive therapyfor COVID-19: the biological and clinical plausibility.Immunopharmacol Immunotoxicol. 2021 Feb;43(1):37-50.doi: 10.1080/08923973.2020.1863984. Epub 2021 Jan 6.PMID: 33406943.

  19. Kunutsor SK, Seidu S, Khunti K. Estatinas y prevenciónprimaria del tromboembolismo venoso: una revisión sistemáticay metanálisis. Lanceta Hematol. 2017;4(2):e83-e93.

  20. Ferrari F, Martins VM, Fuchs FD, Stein R. Renin-angiotensin-aldosterone system inhibitors in COVID-19: A review.Clinics (Sao Paulo) [Internet]. 2021;76(e2342):e2342. Disponibleen: https://www.sciencedirect.com/science/article/pii/S1807593222000904

  21. Liu K, Wang X, Song G. Association of epicardial adiposetissue with the severity and adverse clinical outcomes ofCOVID-19: A meta-analysis. Int J Infect Dis [Internet].2022;120:33-40. Disponible en: https://www.sciencedirect.com/science/article/pii/S1201971222002120

  22. Aparisi Á, Amat-Santos IJ, López Otero D, Marcos-MangasM, González-Juanatey JR, San Román JA. Impactof statins in patients with COVID-19. Rev Esp Cardiol(Engl Ed) [Internet]. 2021;74(7):637-40. Disponibleen: https://www.sciencedirect.com/science/article/pii/S1885585721000256

  23. Daniels LB, Sitapati AM, Zhang J, Zou J, Bui QM, RenJ, Longhurst CA, Criqui MH, Messer K. Relation of statinuse prior to admission to severity and recovery amongCOVID-19 inpatients. Am J Cardiol. 2020;136:149-55.doi: 10.1016/j.amjcard.2020.09.012.

  24. Saeed O, Castagna F, Agalliu I, Xue X, Patel SR, RochlaniY, Kataria L, Vukelic S, Sims DB, Alvarez C, Rivas-LasarteM, García MJ, Jorde UP. Statin use and in-hospital mortalityin Diabetes mellitus and COVID-19. J Am Heart Assoc.2020;9(24):e018475. doi: 10.1161/JAHA.120.018475.

  25. Anklesaria Z, Frankman J, Gordin J, Zhan J, Liu AK. Fatalrhabdomyolysis in a COVID-19 patient on rosuvastatin.Cureus. 2020;12(10):11186. doi: 10.7759/cureus.11186.

  26. Butt JH, Gerds TA, Schou M, Kragholm K, Phelps M,Havers-Borgersen E, Yafasova A, Gislason GH, Torp-PedersenC, Kober L, Fosbol EL. Association between statinuse and outcomes in patients with coronavirus disease 2019(COVID-19): A nationwide cohort study. BMJ Open. 2020;10(12):e044421. doi: 10.1136/bmjopen-2020-044421.

  27. Ferrari F, Martins VM, Teixeira M, Santos RD, Stein R.COVID-19 and thromboinflammation: Is there a role forstatins? Clinics (Sao Paulo) [Internet]. 2021;76(e2518):e2518.Disponible en: https://www.sciencedirect.com/science/article/pii/S1807593222001181

  28. Lima Martínez MM, Contreras MA, Marín W, D’MarcoL. Statins in COVID-19: Is there any foundation? ClínInvestig Arterioscler (Engl Ed) [Internet]. 2020;32(6):278-81. Disponible en: https://www.sciencedirect.com/science/article/pii/S2529912320300759

  29. Zapata-Cardona MI, Flórez-Álvarez L, Zapata-Builes W, Guerra-Sandoval AL, Guerra-Almonacid CM, Hincapié-GarcíaJ, et al. Atorvastatin Effectively Inhibits Ancestral and TwoEmerging Variants of SARS-CoV-2 in vitro. Front Microbiol.2022 Mar 18;13:721103. doi: 10.3389/fmicb.2022.721103.PMID: 35369500; PMCID: PMC8972052.

  30. Andrews L, Goldin L, Shen Y, Korwek K, Kleja K, PolandRE, Guy J, Sands KE, Perlin JB. Discontinuation of atorvastatinuse in hospital is associated with increased riskof mortality in COVID-19 patients. J Hosp Med. 2022Mar;17(3):169-175. doi: 10.1002/jhm.12789. Epub 2022Feb 14. PMID: 35504528; PMCID: PMC9088329

  31. Proto MC, Fiore D, Piscopo C, Pagano C, Galgani M, BruzzanitiS, et al. Lipid homeostasis and mevalonate pathwayin COVID-19: Basic concepts and potential therapeutictargets. Prog Lipid Res [Internet]. 2021;82(101099):101099.Disponible en: https://www.sciencedirect.com/science/article/pii/S0163782721000151




2020     |     www.medigraphic.com